Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sickle Cell Gene Therapy Reimbursement: Will Experience Matter? And Which Kind?

28 Dec 2023

• By Michael McCaughan

gene therapy reimbursement — Simultaneous approvals are putting a spotlight on gene therapy reimbursement. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Related Content

As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate

11 Aug 2023

Bluebird, Vertex Gene Therapies May Answer $1m Question: Can Competition Reduce Rx Prices?

09 Dec 2023

Bluebird’s Lost Voucher: Lyfgenia Contains Same ‘Active Ingredient’ As Zynteglo, US FDA Says

14 Dec 2023

Medicaid Outcomes-Based Payment Model For Cell, Gene Therapy to Launch In 2025

13 Oct 2023

Pricing Cures For Sickle Cell Disease: Sen. Cassidy Weighs In

14 Feb 2019

Related Companies

Vertex Pharmaceuticals Incorporated

Bluebird Bio

Merck & Co., Inc.

Gilead Sciences, Inc.

Additional Topics

United States Gene Therapy Reimbursement Pricing Debate Medicaid Policy Approvals Rare Diseases BioPharmaceutical Blood & Coagulation Disorders

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.